Alto Neuroscience Sees Unusually High Options Volume (NYSE:ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO) saw some unusual options trading activity on Wednesday. Investors purchased 2,129 call options on the stock. This is an increase of 21% compared to the typical daily volume of 1,755 call options.

Alto Neuroscience Price Performance

Shares of NYSE:ANRO opened at $4.36 on Thursday. Alto Neuroscience has a 1 year low of $4.26 and a 1 year high of $24.00. The firm has a fifty day moving average price of $12.22 and a 200 day moving average price of $12.48. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. On average, equities analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Robert W. Baird dropped their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Wedbush downgraded shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $29.00 to $4.00 in a research note on Wednesday. Finally, Rodman & Renshaw downgraded shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.40.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new stake in Alto Neuroscience during the first quarter valued at about $21,267,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience during the first quarter valued at about $9,788,000. Vanguard Group Inc. bought a new stake in Alto Neuroscience during the first quarter valued at about $8,233,000. Jennison Associates LLC bought a new stake in Alto Neuroscience during the first quarter valued at about $7,039,000. Finally, Artal Group S.A. bought a new stake in shares of Alto Neuroscience in the first quarter valued at about $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.